Prenetics Global (NASDAQ: PRE) reported second-quarter revenue of $46.5 million, a 3.9x increase from the prior year period. The consumer health company raised its full-year revenue guidance to $220-230 million.

The firm turned adjusted free cash flow positive in July for the first time, supported by $1 billion in growth financing from General Catalyst. Management projects revenue of $400 million or more by 2027.

Financial Performance

Total revenue reached $46.5 million in Q2, reflecting a 29% quarter-over-quarter growth. The IM8 brand contributed $45 million to this total, operating at a 65% gross margin. This margin represents an improvement of approximately three full points compared to the same period last year.

Fixed operating costs stood at $8.8 million, or 19% of sales. While this figure was 14% higher than the prior quarter, it was 2.3 times greater than the year-ago period. Contribution profit, defined as gross profit minus operating costs, reached $21.4 million, or 46% of sales. This marks a 16 percentage point improvement in contribution margin versus the prior year.

Marketing and Unit Economics

Acquisition marketing spend totaled $36.2 million, representing 78% of sales. The company acquired 118,000 new customers during the quarter, a 98% increase from the prior quarter. Customer acquisition cost (CAC) remained flat to slightly down at a 1% decrease despite the doubling of spend from Q1.

In July, the company acquired a record 47,373 customers at a CAC of $239, which is roughly 21% lower than the Q2 average. Revenue for July reached $20.9 million, with an annualized running rate of approximately $251 million. Adjusted free cash flow turned positive in July, driven by the General Catalyst facility funding 70% of the acquisition marketing line.

What the Numbers Show

The divergence between rising top-line growth and declining fixed cost leverage highlights the company's operational model. Fixed operating expenses fell 21% quarter-over-quarter as a percentage of sales, while the workforce remained stable at around 70 employees. This indicates that the 3.9x revenue growth is being driven by variable marketing spend rather than proportional increases in headcount or fixed overhead, validating the management's claim of an AI-native organizational structure.

Guidance and Balance Sheet

Management raised full-year total revenue guidance to $220-230 million, with IM8 contributing $215-222 million. For Q3, the company guides to $63-64 million in parent company revenue. The full-year adjusted EBITDA loss is expected to narrow significantly in the second half, dropping to a negative $8-12 million loss from a negative $24.6 million loss in the first half.

The balance sheet shows $109.4 million in cash and current financial assets. The company executed a share buyback of $40 million in the first half, reducing Class A shares outstanding to 13.6 million from 15.3 million at the end of calendar year 2025. Fully diluted shares stand at 19.2 million, including warrants.

Prenetics Global Limited (NASDAQ: PRE) executives Danny Yeung and Brian Rosin purchased $1.0 million of company shares in open market transactions between August 20 and August 25, 2026.

The purchases occurred within the trading window following the release of second quarter 2026 financial results, marking the latest addition to the leadership team’s cumulative personal investment of approximately $3.75 million since November 2025.

Executive Share Purchases

Chief Executive Officer Danny Yeung acquired 24,681 shares for approximately $502,000 at an average price of roughly $20.34 per share across two days of trading on August 20 and August 24, 2026. This transaction brings his cumulative personal investment in the company to approximately $1.75 million since November 2025. Previous purchases included approximately $502,000 in November 2025 and approximately $750,000 in February 2026.

Chief Financial Officer Brian Rosin purchased 23,100 shares for approximately $498,000 at an average price of roughly $21.54 per share on August 24 and August 25, 2026. This marks Rosin’s first open market purchase since joining the company in May 2026.

Neither executive has sold any shares during this period.

Second Quarter Financial Performance

Prenetics reported total second quarter revenue of $46.5 million, representing a 288% increase year over year. The flagship brand IM8 contributed $45.0 million of this revenue, up 359% year over year, marking its sixth consecutive record quarter.

In July 2026, IM8 delivered $20.9 million in revenue, establishing an annualized revenue run-rate of approximately $251 million. The company recorded its first month of positive consolidated Adjusted Free Cash Flow during this period.

Guidance and Strategic Updates

Management raised full year 2026 revenue guidance to a range of $220 million to $230 million. Additionally, Prenetics introduced full year 2027 revenue guidance of more than $400 million.

CEO Danny Yeung cited General Catalyst’s Customer Value Fund commitment of $1 billion in growth financing to IM8 as key validation of the business model. He noted that the company turned consolidated Adjusted Free Cash Flow positive in July alongside the guidance upgrades.

CFO Brian Rosin stated that his capital allocation discipline extends to his personal investments, buying in his first available window after joining the company three months prior.

What the Numbers Show

IM8 accounts for approximately 97% of Prenetics’ total quarterly revenue ($45.0 million out of $46.5 million), highlighting a heavy concentration in the flagship brand despite the company’s broader consumer health positioning.